The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.
 
Eric Xueyu Chen
Honoraria - Eisai
Research Funding - AstraZeneca/MedImmune; Boston Biomedical; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
 
Grainne M. O'Kane
No Relationships to Disclose
 
Warren P. Mason
Expert Testimony - Medcan
 
Jennifer J. Knox
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Merck
Research Funding - AstraZeneca; Ipsen; Merck
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Adaptimmune; Boehringer Ingelheim; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; Lilly; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech
 
Gelareh Zadeh
No Relationships to Disclose